Bank of New York Mellon
UBX

Bank of New York Mellon’s Unity Biotechnology UBX Stock Holding History

Bank of New York Mellon’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,262
Closed -$9K – 4555
2022
Q3 		$9K Hold
2,262
– – ﹤0.01% 4514
2022
Q2 		$13K Hold
2,262
– – ﹤0.01% 4535
2022
Q1 		$25K Hold
2,262
– – ﹤0.01% 4605
2021
Q4 		$33K Sell
2,262
-1,390
-38% -$30.4K ﹤0.01% 4548
2021
Q3 		$109K Buy
3,652
+13
+0.4% +$459 ﹤0.01% 4321
2021
Q2 		$169K Sell
3,639
-6,915
-66% -$333K ﹤0.01% 4132
2021
Q1 		$633K Sell
10,554
-965
-8% -$65.8K ﹤0.01% 3561
2020
Q4 		$603K Buy
11,519
+2,775
+32% +$134K ﹤0.01% 3521
2020
Q3 		$302K Buy
8,744
+44
+0.5% +$2.79K ﹤0.01% 3718
2020
Q2 		$756K Buy
8,700
+679
+8% +$50.3K ﹤0.01% 3259
2020
Q1 		$465K Buy
8,021
+345
+4% +$21.7K ﹤0.01% 3406
2019
Q4 		$554K Buy
7,676
+1,101
+17% +$77.7K ﹤0.01% 3540
2019
Q3 		$402K Sell
6,575
-377
-5% -$26.7K ﹤0.01% 3663
2019
Q2 		$660K Buy
6,952
+612
+10% +$52.1K ﹤0.01% 3461
2019
Q1 		$514K Buy
6,340
+478
+8% +$54.2K ﹤0.01% 3535
2018
Q4 		$953K Buy
5,862
+4,291
+273% +$570K ﹤0.01% 3138
2018
Q3 		$256K Buy
1,571
+454
+41% +$74.8K ﹤0.01% 3866
2018
Q2 		$168K Buy
+1,117
New +$163K ﹤0.01% 3935

Other funds holding UBX

AWA
Arete Wealth Advisors Chicago, Illinois $3.05B AUM 42.78% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon's UBX Position: Q4 2022 in Review

Bank of New York Mellon sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 2,262 shares — an estimated $9K sold.

Bank of New York Mellon first reported a position in UBX in Q2 2018 and held it in 18 quarters. The position peaked at $953K in Q4 2018. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

  • Bank of New York Mellon reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 2,262 Unity Biotechnology shares in Q4 2022, an estimated $9K.
  • Bank of New York Mellon first reported a position in Unity Biotechnology in Q2 2018 and held it in 18 quarters.
  • Bank of New York Mellon's Unity Biotechnology position peaked at $953K in Q4 2018.
  • 54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.